Table.1 Baseline characteristics and clinical outcomes in MINOCA patients with or without hyperuricemia
Variable | Total (n = 1179) | Normouricemia (n = 901) | Hyperuricemia (n = 278) | p value |
|---|---|---|---|---|
Male, n (%) | 867 (73.5%) | 642 (71.2%) | 225 (80.9%) | 0.001 |
Age, years | 55.7 ± 11.8 | 56.6 ± 11.1 | 53.0 ± 13.5 |  < 0.001 |
BMI, kg/m2 | 25.4 ± 3.7 | 25.1 ± 3.5 | 26.5 ± 4.3 |  < 0.001 |
STEMI, n (%) | 475 (40.2%) | 344 (38.1%) | 131 (47.1%) | 0.008 |
Emergent angiography, n (%) | 159 (13.4%) | 125 (13.8%) | 34 (12.2%) | 0.483 |
Past history | Â | Â | Â | Â |
 Hypertension | 630 (53.4%) | 474 (52.6%) | 156 (56.1%) | 0.305 |
 Diabetes | 187 (15.8%) | 151 (16.7%) | 36 (12.9%) | 0.129 |
 Dyslipidemia | 686 (58.1%) | 512 (56.8%) | 174 (62.5%) | 0.089 |
 Previous MI | 58 (4.9%) | 44 (4.8%) | 14 (5.0%) | 0.918 |
 Killip class ≥ 2, n (%) | 89 (7.5%) | 64 (7.1%) | 25 (8.9%) | 0.514 |
 LVEF, % | 60.5 ± 7.5 | 60.8 ± 6.7 | 60.3 ± 8.4 | 0.112 |
 TIMI risk score | 3.4 ± 1.3 | 3.3 ± 1.2 | 3.5 ± 1.3 | 0.076 |
Blood test | Â | Â | Â | Â |
 Uric acid, μmol/L | 343.4 ± 94.2 | 305.1 ± 65.1 | 467.9 ± 59.9 |  < 0.001 |
 FBG, mmol/L | 5.69 ± 1.68 | 5.72 ± 1.72 | 5.66 ± 1.63 | 0.630 |
 TG, mmol/L | 1.44 (1.05, 2.00) | 1.36 (1.03, 1.93) | 1.67 (1.28, 2.29) |  < 0.001 |
 TC, mmol/L | 3.92 ± 0.87 | 3.91 ± 1.01 | 3.92 ± 0.91 | 0.760 |
 LDL-C, mmol/L | 2.29 ± 0.76 | 2.29 ± 0.73 | 2.29 ± 0.83 | 0.971 |
 HDL-C, mmol/L | 1.08 ± 0.29 | 1.11 ± 0.30 | 0.98 ± 0.24 | 0.001 |
 Creatinine, μmol/L | 83.13 ± 15.89 | 82.92 ± 14.90 | 84.23 ± 17.03 | 0.202 |
 hs-CRP, mg/L | 2.20 (1.03, 5.75) | 2.14 (0.96, 5.80) | 2.37 (1.25, 5.69) | 0.128 |
 NT-proBNP, pg/mL | 372 (112, 683) | 368 (108, 672) | 379 (125, 694) | 0.132 |
 Peak TnI, ng/mL | 3.24 (0.72, 6.51) | 3.11 (0.65, 6.41) | 3.35 (0.98, 6.93) | 0.157 |
In-hospital medication | Â | Â | Â | Â |
 DAPT | 1091 (92.5%) | 837 (92.8%) | 254 (91.3%) | 0.396 |
 Statin | 1130 (95.8%) | 861 (95.5%) | 269 (96.7%) | 0.380 |
 Beta-blocker | 860 (72.9%) | 655 (72.6%) | 205 (73.7%) | 0.732 |
 ACEI or ARB | 759 (64.3%) | 572 (63.4%) | 187 (67.2%) | 0.103 |
CV outcomes | Â | Â | Â | Â |
 MACE | 168 (14.2%) | 116 (12.8%) | 52 (18.7%) | 0.015 |
 Death, nonfatal MI, stroke or revascularization | 102 (8.6%) | 69 (7.6%) | 33 (11.8%) | 0.029 |
 All-cause death | 18 (1.5%) | 11 (1.2%) | 7 (2.5%) | 0.123 |
 Nonfatal MI | 41 (3.4%) | 27 (2.9%) | 14 (5.0%) | 0.105 |
 Revascularization | 46 (3.9%) | 33 (3.6%) | 13 (4.6%) | 0.445 |
 Nonfatal stroke | 12 (1.0%) | 7 (0.7%) | 5 (1.7%) | 0.138 |
 Hospitalization for UA | 71 (6.0%) | 56 (6.2%) | 15 (5.3%) | 0.616 |
 Hospitalization for HF | 48 (4.0%) | 27 (2.9%) | 21 (7.5%) | 0.001 |